1. Home
  2. IDYA vs NWN Comparison

IDYA vs NWN Comparison

Compare IDYA & NWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IDEAYA Biosciences Inc.

IDYA

IDEAYA Biosciences Inc.

HOLD

Current Price

$34.91

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

NWN

Northwest Natural Holding Company

HOLD

Current Price

$49.87

Market Cap

2.3B

Sector

Utilities

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDYA
NWN
Founded
2015
1859
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Oil/Gas Transmission
Sector
Health Care
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.3B
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
IDYA
NWN
Price
$34.91
$49.87
Analyst Decision
Strong Buy
Buy
Analyst Count
16
3
Target Price
$52.86
$54.33
AVG Volume (30 Days)
1.2M
257.6K
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
3.71%
EPS Growth
61.90
36.45
EPS
N/A
2.33
Revenue
$218,710,000.00
$1,289,363,000.00
Revenue This Year
N/A
$11.37
Revenue Next Year
$201.05
$4.46
P/E Ratio
N/A
$20.90
Revenue Growth
3024.43
11.83
52 Week Low
$20.50
$39.29
52 Week High
$39.28
$55.99

Technical Indicators

Market Signals
Indicator
IDYA
NWN
Relative Strength Index (RSI) 69.60 51.04
Support Level $32.85 $48.30
Resistance Level $36.01 $50.17
Average True Range (ATR) 1.80 1.08
MACD 0.67 0.12
Stochastic Oscillator 92.17 64.80

Price Performance

Historical Comparison
IDYA
NWN

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

About NWN Northwest Natural Holding Company

Northwest Natural Holding Co is a public natural gas service supplier operating in the U.S. Pacific Northwest. Its subsidiary, NW Natural, operates through the natural gas distribution segment, which purchases and distributes natural gas through which operates in Oregon and southwest Washington. The company operates in three reportable business segments, which are NWN Gas Utility, SiEnergy, and NWN Water. The company generates maximum revenue from NWN Gas Utility segment. It also generates revenue from residential, commercial, and industrial customers, the majority of which are in Oregon. Residential and commercial customers account for the vast majority of profitability.

Share on Social Networks: